Generic Biologics On FDA Fast Track?: “Follow-On” Process Under Debate

Data requirements for generic biologics approved under the 505(b)(2) process will be taken up by FDA over the next six months, Center for Drug Evaluation & Research Director Janet Woodcock, MD, said